All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 59 points (0.3%) at 17,066 as of Monday, March 7, 2016, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,929 issues advancing vs. 976 declining with 157 unchanged.

The Health Care sector currently sits up 5.6% versus the S&P 500, which is up 0.1%. Top gainers within the sector include Opko Health ( OPK), up 8.3%, Intrexon ( XON), up 8.0%, Ionis Pharmaceuticals ( IONS), up 7.5%, Alkermes ( ALKS), up 6.5% and Mallinckrodt ( MNK), up 5.9%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Celldex Therapeutics ( CLDX) is one of the companies pushing the Health Care sector lower today. As of noon trading, Celldex Therapeutics is down $4.04 (-49.3%) to $4.15 on heavy volume. Thus far, 12.0 million shares of Celldex Therapeutics exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $3.70-$4.18 after having opened the day at $3.75 as compared to the previous trading day's close of $8.19.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. Celldex Therapeutics has a market cap of $814.3 million and is part of the drugs industry. Shares are down 47.8% year-to-date as of the close of trading on Friday. Currently there are 9 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Celldex Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and generally disappointing historical performance in the stock itself. Get the full Celldex Therapeutics Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Mednax ( MD) is down $3.09 (-4.5%) to $64.89 on heavy volume. Thus far, 805,600 shares of Mednax exchanged hands as compared to its average daily volume of 826,700 shares. The stock has ranged in price between $63.40-$66.49 after having opened the day at $66.48 as compared to the previous trading day's close of $67.98.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

MEDNAX, Inc., together with its subsidiaries, provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the United States and Puerto Rico. Mednax has a market cap of $6.4 billion and is part of the health services industry. Shares are down 5.1% year-to-date as of the close of trading on Friday. Currently there are 11 analysts that rate Mednax a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Mednax as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Mednax Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Stryker Corporation ( SYK) is down $0.69 (-0.7%) to $102.76 on light volume. Thus far, 477,208 shares of Stryker Corporation exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $102.33-$103.00 after having opened the day at $102.54 as compared to the previous trading day's close of $103.45.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Stryker Corporation, together with its subsidiaries, operates as a medical technology company. It operates through three segments: Orthopaedics; MedSurg; and Neurotechnology and Spine. Stryker Corporation has a market cap of $38.4 billion and is part of the health services industry. Shares are up 11.3% year-to-date as of the close of trading on Friday. Currently there are 14 analysts that rate Stryker Corporation a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Stryker Corporation Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).